[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368560-105":59,"doc-detail-368560-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","should-the-age-range-of-the-dutch-hrhpv-based-cervical-cancer-screening-program-be-broadened-a-modelling-study-using-cohort-effects","Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? - A modelling study using cohort effects","","In the Netherlands, women are invited for human papillomavirus (HPV) screening between ages 30 and 60, with conditional screening at 65, but incidence of cervical cancer has risen among younger women while HPV-vaccinated cohorts reached age 30 in 2023. Microsimulation model MISCAN-Cervix was recalibrated for cohort effects to estimate cost-effectiveness up to age 65 and to assess starting screening at 25 in partly vaccinated cohorts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/should-the-age-range-of-the-dutch-hrhpv-based-cervical-cancer-screening-program-be-broadened-a-modelling-study-using-cohort-effects/368560/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/should-the-age-range-of-the-dutch-hrhpv-based-cervical-cancer-screening-program-be-broadened-a-modelling-study-using-cohort-effects/368560.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What screening age range is used in the Netherlands currently?","Question",{"text":112,"@type":113},"Women are invited every 5 years between ages 30 and 60, with additional conditional screening at 65 depending on prior HPV results. Screening at age 45/55 occurs when women missed prior rounds or had a positive HPV test without referral.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do the authors consider broadening the HPV screening age range?",{"text":117,"@type":113},"Cervical cancer incidence has increased in younger birth cohorts, and HPV-vaccinated cohorts reached screening age 30 in 2023. The authors also consider increased healthy life expectancy for older women and the possibility that harms and benefits may differ by age.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the modelling study find about expanding screening to ages 25 or 65?",{"text":121,"@type":113},"Adding screening at age 65 to the current strategy increased cancers prevented (+3.5%) and life years gained (+2.4%) but also raised costs substantially (+57.0%), resulting in a cost-effectiveness ratio of €275,096/LYG. Starting screening at age 25 increased cancers prevented and life years gained but also increased referrals and costs, yielding a cost-effectiveness ratio of €120,017–€323,813/LYG.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368560,1790664153,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","DOI: 10.1002/ijc.35435  \nSHORT REPORT  \nCancer Therapy a nd Prevention  \nShould the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects  \nSylvia Kaljouw  | Erik E. L. Jansen  | Veerle J. C. Schevenhoven  | Inge M. C. M. de Kok   \nDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands  \nCorrespondence  \nSylvia Kaljouw, Erasmus MC, Department of Public Health, office Na2401,  \nDr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.  \nEmail: [kaljouw@eshpm.eur.nl](kaljouw@eshpm.eur.nl)  \nFunding information  \nRijksinstituut voor Volksgezondheid en Milieu  \nAbstract  \nIn the Netherlands, women are invited for human papillomavirus (HPV) screening between the ages of 30 and 60 (with conditional screening at age 65) . However, an increase in cervical cancer (CC) incidence has been observed in younger women recently. Meanwhile, HPV-vaccinated cohorts reached the screening age of 30 in 2023. Moreover, increasing healthy life expectancy is a consideration for screening in older age groups. Due to these developments, the starting and ending ages of the HPV screening programs should be reconsidered. Microsimulation model MISCAN-Cervix was recalibrated for cohort effects using updated CC incidence data. We used this model to calculate the cost-effectiveness of screening unvaccinated women in birth cohorts 1962–1992 until 65 years old. Additionally, we considered starting screening at 25 for partly vaccinated cohorts (born in 2002–2006) . Vaccination effects were calculated using microsimulation model STDSIM. Main outcome measures included cancers prevented, life years gained (LYG), costs, and referrals compared to the current strategy (2027 onwards) . Adding screening at age 65 to the current strategy leads to +3 . 5% cancers prevented, +10 .3% referrals, +2 .4% LYG and +57 .0% costs (cost-effectiveness ratio: €275,096/LYG) . Adding screening at age 25 results in extra cases prevented (+1.3%–5.7%, depending on the target group's vaccination status) and LYG (+0.8%–3.7%), but increases referrals (12.9%–37.1%) and costs (+14 .0%–33 . 1%) (cost-effectiveness ratio: €120,017–€323,813/LYG) . So, screening unvaccinated women at 65 years old and screening women in (partly-)vaccinated cohorts at age 25 might not represent good value for money.  \nKEYWOR DS  \nage range, cohort effects, HPV vaccination, hrHPV-based screening, simulation model  \nAbbreviations: ASC-US, atypical squamous cells of undetermined significance; CC, cervical cancer; CER, cost-effectiveness ratio; CIN, cervical intraepithelial neoplasia; FIGO, International Federation of Gynecology and Obstetrics; HPV, Human papillomavirus; Hr, high risk; HSIL, high-grade squamous intraepithelial lesion; LYG, Lifeyears gained; NNR, Number needed to refer; NNS, Number needed to screen; OHR, other high risk; PPV, positive predictive value; QALY, quality adjusted lifeyear.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nWhat's New?  \nCervical cancer incidence in the Netherlands is increasing among women in younger birth cohorts. This raises concerns about the start and end ages of the country's human papillomavirus (HPV) screening program, which currently includes women ages 30 to 60. Here, the authors estimated the impact of a broader HPV screening age range on cancer prevention and costs in the Netherlands. Models show that expanding screening to cover women ages 25 to 65 modestly benefits cancer prevention and significantly increases unnecessary referrals. The findings indicate that expanding the HPV screening age range to include younger and older women is not cost-effective.  \n1 | INTRODUCTION  \nIn the Nethe","cbCaioAYt50JZNjs","https://ap.wps.com/l/cbCaioAYt50JZNjs","pdf",1027738,"English","# Introduction\n## Background on the current Dutch HPV screening age range\n## Rationale for reconsidering start and end ages","[{\"question\":\"What screening age range is used in the Netherlands currently?\",\"answer\":\"Women are invited every 5 years between ages 30 and 60, with additional conditional screening at 65 depending on prior HPV results. Screening at age 45/55 occurs when women missed prior rounds or had a positive HPV test without referral.\"},{\"question\":\"Why do the authors consider broadening the HPV screening age range?\",\"answer\":\"Cervical cancer incidence has increased in younger birth cohorts, and HPV-vaccinated cohorts reached screening age 30 in 2023. The authors also consider increased healthy life expectancy for older women and the possibility that harms and benefits may differ by age.\"},{\"question\":\"What did the modelling study find about expanding screening to ages 25 or 65?\",\"answer\":\"Adding screening at age 65 to the current strategy increased cancers prevented (+3.5%) and life years gained (+2.4%) but also raised costs substantially (+57.0%), resulting in a cost-effectiveness ratio of €275,096/LYG. Starting screening at age 25 increased cancers prevented and life years gained but also increased referrals and costs, yielding a cost-effectiveness ratio of €120,017–€323,813/LYG.\"}]","Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? - A modelling study using cohort effects | PDF",1790177494,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ada400be5efa8992266c5b18437bf134.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0237f24959fd7976f265bb48df53e65.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb2314cf82df7385944b7f025b0a819c.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46b86d07a8b7e8ace1bc9011a545794e.webp",980,1287]